Article: Schering-Plough chief stands by Vytorin.(TOP STORIES)(Brief article)

Schering-Plough Chief Stands by Vytorin. Schering-Plough Corp. (Kenilworth NJ) Chief Executive Fred Hassan says the company stands by the effectiveness of its cholesterol drug Vytorin after a study showed it may work no better than an older, less expensive medicine. Doctors and investors said the data on Vytorin, released last week, may hurt sales of the drug. It is "very early to make too many judgments and decisions because the data isn't all out yet," Hassan said, adding he was surprised by the reaction. Schering fell 23% for the week to $21.28 after the company released data showing Vytorin reduced artery-clogging plaque no better than a generic form of Zocor. Vytorin ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!